Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 2:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Infusion of MSCs Clear all
Withdrawn Phase 2 Interventional

Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHD

NCT05333029
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Allogeneic mesenchymal stromal cells (MSCs), Extracorporeal photopheresis (ECP)
Biological
Lead sponsor
Molly Gallogly
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Sep 24, 2026, 2:25 AM EDT
Completed Phase 1 Interventional

Pilot Trial of Mesenchymal Stem Cells for Systemic Lupus Erythematosus

NCT03171194
View directory record Official record
Conditions
System; Lupus Erythematosus
Interventions
Low Dose Mesenchymal Stem Cells (MSCs)
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Sep 24, 2026, 2:25 AM EDT
Suspended Phase 1 Interventional

Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines

NCT02962661
View directory record Official record
Conditions
Cardiomyopathy, Heart Failure, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Best Practice, Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 24, 2026, 2:25 AM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Mesenchymal Stem Cells for Age-Related Frailty

NCT05284604
View directory record Official record
Conditions
Frailty
Interventions
Mesenchymal Stem Cells (MSCs)
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2023 · Synced Sep 24, 2026, 2:25 AM EDT
Completed Phase 2 Interventional Results available

Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease

NCT04506073
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Mesenchymal Stem Cells, Placebo
Drug
Lead sponsor
Mya Schiess
Other
Eligibility
50 Years to 79 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 24, 2026, 2:25 AM EDT
Terminated Phase 1 Interventional Results available

Safety and Efficacy of Allogeneic MSCs in Promoting T-regulatory Cells in Patients With Small Abdominal Aortic Aneurysms

NCT02846883
View directory record Official record
Conditions
Abdominal Aortic Aneurysm
Interventions
1 million MSCs/kg, 3 million MSCs/kg, Placebo
Biological · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 24, 2026, 2:25 AM EDT
Completed Phase 1 Interventional

Repeated Infusions of Mesenchymal Stromal Cells in Children With Osteogenesis Imperfecta

NCT01061099
View directory record Official record
Conditions
Osteogenesis Imperfecta Type II, Osteogenesis Imperfecta Type III
Interventions
Mesenchymal Stromal Cells
Biological
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Up to 19 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Sep 24, 2026, 2:25 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Autologous Bone Marrow Aspirate (IV) and Bone Marrow Concentrate (Intranasal) for Parkinson's Disease and Parkinson-Plus Syndromes (SPARC-PD)

NCT07751640
View directory record Official record
Conditions
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
Interventions
Autologous Bone Marrow Aspirate (BMA) and Bone Marrow Aspirate Concentrate (BMAC)
Biological
Lead sponsor
Apeiron Research Center
Other
Eligibility
40 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 24, 2026, 2:25 AM EDT
Completed Phase 1 Interventional

Mesenchymal Stem Cell and Islet Co-transplantation

NCT02384018
View directory record Official record
Conditions
Chronic Pancreatitis, Diabetes
Interventions
autologous mesenchymal stromal cell
Biological
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 69 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 24, 2026, 2:25 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression.

NCT03059355
View directory record Official record
Conditions
Endothelial Dysfunction, Metabolic Syndrome, Chronic Inflammation
Interventions
UCMSCs, BMMSCs, Placebo
Biological · Other
Lead sponsor
Joshua M Hare
Other
Eligibility
21 Years to 95 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 24, 2026, 2:25 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of UCB and MSCs in Children With CP: ACCeNT-CP

NCT03473301
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Infusion of allogeneic umbilical cord blood, Infusion of MSCs
Biological
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
24 Months to 60 Months
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Sep 24, 2026, 2:25 AM EDT
Recruiting Phase 2 Interventional

A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)

NCT04042844
View directory record Official record
Conditions
Lumbar Disc Disease
Interventions
BRTX-100, Saline
Biological · Drug
Lead sponsor
BioRestorative Therapies
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Santa Monica, California • Walnut Creek, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Sep 24, 2026, 2:25 AM EDT
Completed Phase 1 Interventional

Bone Marrow Derived Mesenchymal Stem Cells in Improving Heart Function in Patients With Heart Failure Caused by Anthracyclines

NCT02408432
View directory record Official record
Conditions
Cardiomyopathy, Heart Failure
Interventions
Laboratory Biomarker Analysis, Standard of Care, Mesenchymal Stem Cell Transplantation
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Sep 24, 2026, 2:25 AM EDT
Recruiting Phase 2 Interventional

Single or Repeated Intravenous Administration of umbiliCAl Cord Mesenchymal sTrOmal Cells in Ischemic Cardiomyopathy

NCT06145035
View directory record Official record
Conditions
Ischemic Heart Disease
Interventions
umbilical cord-derived mesenchymal stromal cells (UC-MSCs)
Biological
Lead sponsor
Roberto Bolli
Other
Eligibility
21 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Miami, Florida • Louisville, Kentucky • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 24, 2026, 2:25 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia

NCT04565665
View directory record Official record
Conditions
COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Best Practice, Mesenchymal Stem Cell
Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 24, 2026, 2:25 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19

NCT04362189
View directory record Official record
Conditions
COVID-19
Interventions
HB-adMSC, Placebo
Biological · Other
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Sep 24, 2026, 2:25 AM EDT
Completed Phase 1 Interventional

hCT-MSCs for Children With Autism Spectrum Disorder (ASD)

NCT03099239
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder, ASD
Interventions
hCT-MSC infusion
Biological
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
2 Years to 11 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Sep 24, 2026, 2:25 AM EDT
Completed Phase 1 Interventional

BMT Autologous MSCs for GvHD

NCT02359929
View directory record Official record
Conditions
Graft Versus Host Disease, Acute Graft Versus Host Disease, Chronic Graft Versus Host Disease
Interventions
Autologous mesenchymal stromal cells (MSCs)
Biological
Lead sponsor
Emory University
Other
Eligibility
12 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Sep 24, 2026, 2:25 AM EDT
Completed Phase 2 Interventional

PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00683722
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema, Chronic Bronchitis
Interventions
Prochymal™, Placebo
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Los Angeles, California • Torrance, California • Charlotte, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 24, 2026, 2:25 AM EDT
Terminated Phase 3 Interventional

MSCs in COVID-19 ARDS

NCT04371393
View directory record Official record
Conditions
Mesenchymal Stromal Cells, Remestemcel-L, Acute Respiratory Distress Syndrome, COVID
Interventions
Remestemcel-L, Placebo
Biological · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
21
States / cities
Gilbert, Arizona • Los Angeles, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 24, 2026, 2:25 AM EDT
Completed Phase 1 Interventional

Study of hCT-MSC in Newborn Infants With Moderate or Severe HIE

NCT03635450
View directory record Official record
Conditions
Moderate to Severe Hypoxic-ischemic Encephalopathy
Interventions
Infusion of hCT-MSC
Biological
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
0 Hours to 48 Hours
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Sep 24, 2026, 2:25 AM EDT
Active, not recruiting Phase 2 Interventional

Mesenchymal Stromal Cells in Living Donor Kidney Transplantation

NCT03478215
View directory record Official record
Conditions
Renal Transplantation, Mesenchymal Stem Cells
Interventions
Mesenchymal Stromal Stem Cells (MSCs) Infusion, Normal Saline (Placebo) Infusion
Biological · Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Sep 24, 2026, 2:25 AM EDT
Completed Phase 1 Interventional

Tolerance by Engaging Antigen During Cellular Homeostasis

NCT03504241
View directory record Official record
Conditions
Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient
Interventions
Donor-derived Mesenchymal Stromal Cells, alemtuzumab, belatacept, sirolimus, mycophenolate mofetil, mycophenolate acid, prednisone
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 24, 2026, 2:25 AM EDT